2024
Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison
Bar N, Diels J, van Sanden S, Mendes J, Hernando T, Burnett H, Cost P, Schecter J, Lendvai N, Patel N, Ishida T, Er J, Harrison S, Lopez-Muñoz N. Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison. Current Medical Research And Opinion 2024, 40: 1597-1603. PMID: 39129504, DOI: 10.1080/03007995.2024.2391112.Peer-Reviewed Original ResearchRelapsed/refractory multiple myelomaEfficacy of ciltacabtagene autoleucelIde-celProgression-free survivalCilta-celIdecabtagene vicleucelCiltacabtagene autoleucelMultiple myelomaTreated with 2Risk of disease progressionDistribution of prognostic factorsIndirect comparisonsRefractory multiple myelomaTreatment of patientsCox proportional hazards modelsMatching-adjusted indirect comparisonWeighted Cox proportional hazards modelsLogistic regression analysisProportional hazards modelCARTITUDE-1Partial responseTriple-classPrognostic factorsPatient-level dataClinical benefit
2021
Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Liu Y, Kywe B, Crawford L, Lora F, Bar N, Browning S, Gorshein E, Parker T, Neparidze N. Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience. Blood 2021, 138: 1635. DOI: 10.1182/blood-2021-146619.Peer-Reviewed Original ResearchAutologous stem cell transplantMedian overall survivalInternational Staging System stage IIRefractory multiple myeloma patientsOverall survivalMultiple myeloma patientsMultiple myelomaInduction therapyPartial responsePrimary refractoryInduction regimenMyeloma patientsMonoclonal antibodiesPlasma cellsInternational Myeloma Working Group criteriaYale New Haven Health SystemStage IIHigh-risk cytogeneticsGood partial responseRetrospective cohort studyMajority of patientsMRD-negative statusMonoclonal antibody therapyStem cell transplantImportant prognostic value